Active Filter(s):
Details:
Through the acquisition, Assertio will expand its product portfolio by including Rolvedon (eflapegrastim-xnst), a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation for the treatment of febrile neutropenia.
Lead Product(s): Eflapegrastim-xnst
Therapeutic Area: Infections and Infectious Diseases Product Name: Rolvedon
Highest Development Status: Approved Product Type: Large molecule
Recipient: Spectrum Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 31, 2023
Details:
Through the acquisition, Assertio will expand its product portfolio by including Rolvedon (eflapegrastim-xnst), a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation for the treatment of febrile neutropenia.
Lead Product(s): Eflapegrastim-xnst
Therapeutic Area: Hematology Product Name: Rolvedon
Highest Development Status: Approved Product Type: Large molecule
Recipient: Spectrum Pharmaceuticals
Deal Size: $757.0 million Upfront Cash: $291.0 million
Deal Type: Acquisition April 25, 2023
Details:
SYMPAZAN (clobazam) is the first and only FDA-approved oral film formulation of clobazam, a benzodiazepine approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.
Lead Product(s): Clobazam
Therapeutic Area: Neurology Product Name: Sympazan
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: LGS Foundation
Deal Size: $0.1 million Upfront Cash: Undisclosed
Deal Type: Partnership January 17, 2023
Details:
Sympazan® (clobazam), oral film developed with PharmFilm® technology, is a prescription medicine used to treat seizures associated with Lennox-Gastaut Syndrome in people 2 years of age or older. Clobazam positive allosteric modulator of GABA receptor.
Lead Product(s): Clobazam
Therapeutic Area: Neurology Product Name: Sympazan
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Under the terms of the definitive agreement, Aquestive exclusively licensed the product’s intellectual property to Assertio for an upfront payment. Aquestive also entered into a long-term supply agreement with Assertio for Sympazan (clobazam) oral film.
Lead Product(s): Clobazam
Therapeutic Area: Neurology Product Name: Sympazan
Highest Development Status: Approved Product Type: Small molecule
Recipient: Aquestive Therapeutics
Deal Size: Undisclosed Upfront Cash: $9.0 million
Deal Type: Licensing Agreement October 27, 2022
Details:
The merger creates a growing commercial pharmaceutical company with neurology, inflammation and pain products.
Lead Product(s): Diclofenac Potassium
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Assertio Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 20, 2020
Details:
The Merger will create a leading commercial pharmaceutical company with neurology, inflammation and pain products.
Lead Product(s): Gabapentin
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Assertio Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 16, 2020
Details:
Assertio Therapeutics has entered into a definitive agreement with Collegium Pharmaceutical, Inc. under which Collegium will acquire the NUCYNTA® franchise of products from the Company.
Lead Product(s): Tapentadol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Collegium Pharmaceutical
Deal Size: $375.0 million Upfront Cash: $375.0 million
Deal Type: Agreement February 06, 2020